The cancer-related hyperactivity of NRF2 signalling drives an overexpression of target genes located in permissive chromatin [284] but, in some cancers, such as non-small-cell lung cancer, also enhances reprogramming revealing novel cancer-specific ARE targets for NRF2 binding occurs [304]. The gene discussed is NFE2L2; the disease is cancer.